



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

February 18, 2020

Via E-mail  
Jerald Korn  
General Counsel  
Kaleido Biosciences, Inc.  
65 Hayden Avenue  
Lexington, MA 02421

**Re: Kaleido Biosciences, Inc.  
Form 8-K  
Exhibit No. 10.1 - Credit Agreement, dated October 25, 2019, by and among Kaleido  
Biosciences, Inc., Cadena Bio, Inc. and JPMorgan Chase Bank, N.A.  
Filed October 30, 2019  
File No. 001-38822**

Dear Mr. Korn:

We have concluded our assessment of your redacted exhibit for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance